secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001104659-23-116005
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma Therapeutics reports Q3 2023 net loss of $21.4M; cash $94.1M funds into Q1 2025
--------------------------------------------------------------------------------

- Net loss of $21.4M for Q3 2023 vs. $18.3M for Q3 2022.
- Cash, cash equivalents and marketable securities of $94.1M as of Sept 30, 2023.
- R&D expenses $19.6M, up $4.0M YoY, driven by CT-0525 preclinical costs.
- Selected clinical candidate for CT-1119 (anti-mesothelin CAR-Monocyte); IND targeted for 2025.
- Updated Phase 1 data for CT-0508 shows safety and biomarker correlation with stable disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465923116005/0001104659-23-116005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465923116005/tm2330254d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer